🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

BYND Cannasoft sets $7 million public offering price

EditorEmilio Ghigini
Published 2024-03-12, 09:44 a/m
© Reuters.
BCAN
-

ASHKELON, Israel and VANCOUVER, British Columbia - BYND Cannasoft Enterprises Inc. (Nasdaq:BCAN) (CSE:BYND), an Israeli-based software and cannabis company, has announced the pricing of its underwritten public offering, aiming to raise approximately $7 million before fees and expenses. The offering comprises over 116 million units at a price of $0.06 each, with an alternative for pre-funded warrants at $0.0599.

Each unit sold in the offering includes one common share or a warrant to purchase a common share, along with additional warrants to buy more shares at future dates. The Series A Warrants have an exercise price of $0.09 per share, are exercisable immediately, and expire 30 months post-issuance. Series B Warrants, also immediately exercisable, are priced at $0.102 per share and have a longer lifespan, expiring 60 months after issuance.

Aegis Capital Corp. has been given a 45-day option to purchase additional securities to cover over-allotments, potentially increasing the total proceeds.

The offering is expected to close around March 14, 2024, contingent on standard closing conditions. BYND Cannasoft intends to use the net proceeds for general corporate purposes and working capital.

Aegis Capital Corp. is serving as the sole book-running manager for the offering, with various legal counsels assisting both the company and Aegis.

The offering follows a registration statement filed with the U.S. Securities and Exchange Commission, which became effective on March 11, 2024. Details of the offering will be available in a final prospectus on the SEC's website.

BYND Cannasoft is known for its CRM software, Benefit CRM, and is developing a new platform tailored to the medical cannabis industry. Additionally, the company is working on the EZ-G device, a therapeutic product utilizing CBD oil, pending regulatory approvals.

This news is based on a press release statement and provides information about the company's offering without suggesting investment actions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.